FOLFOX4方案ELFP方案治疗晚期胃癌的疗效比较  

Compariosn of FOLFOX4 regimen and ELCP regimen in the treatment on patients with advanced gastric carcinoma

作　　者：辛德质 

机构地区：[1]山东省莱阳市城厢医院,山东莱阳265200

出　　处：《世界肿瘤杂志》2008年第4期299-301,共3页Tumour Journal of the World

摘　　要：目的比较FOLFOX4方案和ELF方案治疗晚期胃癌的临床疗效及不良反应。方法将40例经病理确诊的晚期胃癌病人随机分为两组。治疗组20例，采用FOLFOX4方案化疗：奥沙利铂（L—OHP）85mg/m^2，静脉滴注2h，d1；亚叶酸钙（cF）200mg/m^2，静脉滴注2h，d1、d2；氟尿嘧啶（5-FU）400mg/m^2，静脉推注，d1、d2；氟尿嘧啶600mg／m^2，持续静脉泵输注22h，d1、d2。每2wk为一疗程。对照组20例，采用ELCP方案化疗：足叶乙甙（Vp-16）120mg/m^2，静脉滴注，d1-d5；亚叶酸钙（CF）200mg/m^2，静脉滴注，d1-d3；氟尿嘧啶（5-Fu）500mg／m^2，静脉滴注5h以上，d1-d5；顺铂（DDP）20mg/m^2，静脉滴注2h，d1司5。每4wk为1周期。对两组的缓解率、生活质量改善率、不良反应发生率进行分析比较。结果治疗组与对照组的缓解率分别为60％和50％，无显著性差异（P〉0．05）；生活质量改善率分别为75％和45％，有显著性差异（P〈0．05）；两组主要不良反应白细胞减少、口腔溃疡、神经毒性和脱发等指标的差异具有显著性（P〈0．05）。结论FOLFOX4方案和ELCP方案治疗晚期胃癌近期疗效较好，不良反应较轻；在生活质量改善方面，FOLFOX4方案优于ELCP方案（P〈0．05）。Objective To compare the efficacy and toxicity of FOLFOX4 regimen and ELCP regimen in the treatment on patients with advanced gastric carcinoma（AGG）. Methods Fifty patients with AGG were divided into two groups randomly. FOLFOX4 regimen： L- OHP （85mg/m^2 iv 2h d1） were given first, CF （200mg/m^2 iv 2h d1, d2） followed by 5-FU （400ms/m^2 iv d1, d2） and 5-FU （600mg/m^2 civ 22h d1,d2）were given. FOLFOX4 regimen Was repearted every 14 days. ELCP regimen： Vp-16（120mg/m2 iv d1-d5） were given first, CF（200mg/m2 iv 2h d1-d5）were given. ELCP regimen Was repeated every 28 days. The overall rate of response. improvement of QOL and toxicity for the two regimens were analysed. Results Theresponse rate（RR）of FOLFOX4 and ELCP were 60% and 50%, respectively. There Was no significant diference （P〉0.05）. The improvement of QOL of FOLFOX4 and ELCP were 76% and 45%, respectively. There Was significant diference （P〈0.05）. The major side efect of the two groups had significant diference. Conclusions FOLFOX4 regimen and ELCP regimen show good eficacy in AGG. The toxicity is mild and tolerable. On the improvement of QOL, FOLFOX4 regimen is better than ELCP regimen.

关 键 词：晚期胃癌 化学治疗 奥沙利铂 氟尿嘧啶 足叶乙甙 顺铂 亚叶酸钙 

分 类 号：R735.2[医药卫生—肿瘤] R73-361[医药卫生—临床医学]